MedTrace Logo

MicroPort® Endoscopic Instrument Control System to Accomplish Robotic-assisted Surgery in Urology

NCT04404738 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2020-09-01

No results posted yet for this study

Summary

Laparoscopy, now virtually completely, was replaced with robotic surgery in uro-oncological surgery in the world. And given the significant increase in the number of robotic surgeries for prostate, bladder and kidney cancer, it is now a major domain in oncological surgery. Microport MedBot Inc. has independently developed a domestic surgical robot in China. Therefore, the purpose of the study is to evaluate the safety and efficacy of the Chinese robot when applied to surgery in oncology.

Conditions

  • Robotic Surgical Procedures
  • Prostatectomy
  • Nephrectomy

Interventions

PROCEDURE

MicroPort® robot-assisted laparoscopic surgery

In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by Microport® Surgical System

PROCEDURE

da Vinci robot-assisted laparoscopic surgery

In this group, patients undergoing robot-assisted laparoscopic surgery in urology will be performed by da Vinci Surgical System

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Xu Gao, professor · Changhai Hospital

  • Jianming Guo, professor · Shanghai Zhongshan Hospital

  • Wei Xue, professor · RenJi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2022-09-30
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04404738 on ClinicalTrials.gov